Novartis ends development of KRAS drug, citing 'increasing options available'
Novartis will stop developing a KRAS lung cancer drug that had made it to Phase 3 testing, a spokesperson confirmed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
